More positive data on icotrokinra have lent support to Johnson & Johnson’s claim that its first-in-class oral therapy has to potential to set a new standard of treatment in plaque psoriasis.
J&J Dreams Of ICONIC Status For Icotrokinra
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
